NO20002831L - Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette - Google Patents

Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette

Info

Publication number
NO20002831L
NO20002831L NO20002831A NO20002831A NO20002831L NO 20002831 L NO20002831 L NO 20002831L NO 20002831 A NO20002831 A NO 20002831A NO 20002831 A NO20002831 A NO 20002831A NO 20002831 L NO20002831 L NO 20002831L
Authority
NO
Norway
Prior art keywords
drug
soft pellet
soft
preparing
methods
Prior art date
Application number
NO20002831A
Other languages
English (en)
Other versions
NO20002831D0 (no
Inventor
Hiromitsu Yoshida
Hideki Ito
Yasuko Soeda
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20002831D0 publication Critical patent/NO20002831D0/no
Publication of NO20002831L publication Critical patent/NO20002831L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Et medikament i myk pelletform egnet for inhalering som er lett å håndtere i farmasøytisk fremstilling, som ikke gir følelse av irritasjon hos brukeren og tillater kontroll av medikamentpartikkel-størrelsesfordelingen ved inhalering. Medikamentet i myk pelletform kan fremstilles ved oppløsning eller suspendering av en medisinsk forbindelse med selvagglomererende egenskaper i en væske inneholdende et sukker, slik som laktose, tørking av den dannede oppløsning eller suspensjon, pulverisering av resten og forming av den dannede pulverblanding til myke pelleter med en gjennomsnittlig partikkeldiameter fra 100 um til 1 mm ved hjelp av tromling i en rotasjonstrommel eller liknende.
NO20002831A 1997-12-03 2000-06-02 Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette NO20002831L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33322897 1997-12-03
PCT/JP1998/005159 WO1999027911A1 (fr) 1997-12-03 1998-11-16 Medicament en pastilles souples et procede de fabrication

Publications (2)

Publication Number Publication Date
NO20002831D0 NO20002831D0 (no) 2000-06-02
NO20002831L true NO20002831L (no) 2000-08-03

Family

ID=18263764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002831A NO20002831L (no) 1997-12-03 2000-06-02 Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette

Country Status (16)

Country Link
EP (1) EP1036562A1 (no)
KR (1) KR20010032303A (no)
CN (1) CN1283991A (no)
AR (1) AR015491A1 (no)
AU (1) AU1054399A (no)
BR (1) BR9815345A (no)
CA (1) CA2310826A1 (no)
HU (1) HUP0004821A2 (no)
ID (1) ID28057A (no)
IL (1) IL136251A0 (no)
NO (1) NO20002831L (no)
NZ (1) NZ504711A (no)
PL (1) PL340736A1 (no)
TR (1) TR200001596T2 (no)
WO (1) WO1999027911A1 (no)
ZA (1) ZA9810882B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005004875A1 (ja) * 2003-07-14 2005-01-20 Sankyo Company, Limited 経肺投与用医薬組成物
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
AU2008282261A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
PH12014500551A1 (en) 2011-09-14 2014-04-21 Shionogi & Co Pharmaceutical composition for inhalation
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
EP3854385A1 (en) * 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5607662A (en) * 1992-03-10 1997-03-04 Fisons, Plc Pharmaceutical inhalation compositions
WO1994014490A1 (de) * 1992-12-23 1994-07-07 Bernhard Hugemann Verfestigter arzneistoffvorrat für die mechanische erzeugung inhalierbarer wirkstoffpartikel
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
JPH08291072A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 吸入用粉末製剤用結晶とその製造方法

Also Published As

Publication number Publication date
PL340736A1 (en) 2001-02-26
NO20002831D0 (no) 2000-06-02
KR20010032303A (ko) 2001-04-16
NZ504711A (en) 2002-02-01
AU1054399A (en) 1999-06-16
CN1283991A (zh) 2001-02-14
CA2310826A1 (en) 1999-06-10
WO1999027911A1 (fr) 1999-06-10
AR015491A1 (es) 2001-05-02
TR200001596T2 (tr) 2000-12-21
BR9815345A (pt) 2000-11-21
HUP0004821A2 (hu) 2001-06-28
IL136251A0 (en) 2001-05-20
EP1036562A1 (en) 2000-09-20
ZA9810882B (en) 1999-05-26
ID28057A (id) 2001-05-03

Similar Documents

Publication Publication Date Title
NO20002831L (no) Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette
AU692550B2 (en) Fluoxetine pharmaceutical formulations
CA2277913A1 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
SE0002822L (sv) Elektropulver
NZ535284A (en) Microparticles of glycopyrrolate for the treatment of respiratory diseases
AU1537095A (en) Therapeutic agents containing thyroid hormones
IS5110A (is) Ný lyfjablanda til innöndunar með eðlisþyngd í lausu sem er frá 0,28 til 0,38 g/ml, sem inniheldur búdesóníð
KR880004805A (ko) 분무건조된 아세트아미노펜
PL334528A1 (en) Novel inhalable preparation of 0.28 to 0.38 g/ml bulk density containing formotherol
NZ236631A (en) Process for the preparation of a spray dried powdered pharmaceutical formulation of naproxen
EE9900293A (et) Uus inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, selle valmistamise protsess ja kasutamine
JPH0529205B2 (no)
ES2179729A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
US5026706A (en) Method for treating dysuria using naftopidil
JP5610670B2 (ja) 防風通聖散配合製剤
CA2265198A1 (en) Method of producing a nicotine medicament and a medicament made by the method
JPS61194031A (ja) 制癌作用増強剤
CN1140062A (zh) 戒烟穴贴膏
ES2282633T3 (es) Un procedimiento para mejorar propiedades superficiales de comprimidosfarmaceuticos.
CN108272904A (zh) 一种后遗影响低的麻醉用植物提取物及其制造方法
CN106798732A (zh) 一种头孢克肟分散片及制备方法
KR880012206A (ko) 구강질환 치료 조성물

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application